Partnered Programs

Global Collaboration and License Agreement with Novo Nordisk

In May 2025, we announced a global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize oral small molecule medicines for obesity and other cardiometabolic diseases. The companies are pursuing multiple R&D programs spanning five GPCR targets, including the GLP-1, GIP and glucagon receptors. Under the terms of the agreement, Septerna will receive an upfront payment of $195 million and is eligible to receive up to approximately $500 million in research, development and commercial milestone payments for each program. Septerna is also eligible to receive tiered royalties on global net sales of marketed products. Novo Nordisk is responsible for all research and development expenses for programs under the collaboration.

Novel GPCR-targeted Program Acquired by Vertex Pharmaceuticals

In September 2023, we signed an asset purchase agreement with Vertex Pharmaceuticals under which Vertex acquired an undisclosed discovery-stage GPCR program. Under the terms of the agreement, Vertex is responsible for continuing the research and development of the novel GPCR program. Septerna received a $47.5 million upfront payment and is eligible for additional payments related to the use of the company’s GPCR Native Complex Platform™ and a preclinical milestone.